About the Journal
The Canadian Journal of General Internal Medicine (CJGIM) ISSN: 2369-1778 is the official publication of the Canadian Society of Internal Medicine (CSIM). The journal has a well respected editorial board and provides a sharp focus on the topics and issues facing the profession of Internal Medicine with a combination of society news, clinical and scientific original articles. CJ
Read More
Current Issue
Vol. 17 No. SP2 (2022): CJGIM Special Issue 2: SGLT2 Inhibitors
SGLT-2 inhibitors have proven to be an effective treatment for glycemic control in type 2 diabetes mellitus. The indications for SGLT-2 have been expanding beyond glycemic control and now include chronic kidney disease and heart failure. These broadened indications mean more GIM physicians will be prescribing this class of medication to help improve the quality of life in patients. With this in mind, we are very pleased to publish this special supplement to the Canadian Journal of General Internal Medicine on the topic of SGLT-2 Therapy and its recent advancements and usage. These articles have been written by leading specialists, providing the reader with practical, clinically relevant and timely information.
Special thanks to Eli Lilly Canada and Boehringer Ingelheim Canada for their unrestricted support of this special issue. Both companies had no input on the content, scope focus or author selection and were not involved in any review process.
Original Research
The Why and How of SGLT2 Inhibitors in CKD
Abstract 41 | PDF Downloads 47 XML Downloads 13 HTML Downloads 10Page 1-8
SGLT2 Inhibitor Use in Patients with Type 2 Diabetes Mellitus and Heart Failure
Abstract 44 | PDF Downloads 44 XML Downloads 14 HTML Downloads 17Page 9-16
A Practical, Simple Approach to Prescribing SGLT-2 Inhibitors for Glycemic Control, Heart Failure, or Chronic Renal Disease in Patients with and without Type 2 Diabetes Mellitus
Abstract 52 | PDF Downloads 40 XML Downloads 12 HTML Downloads 9Page 17-21